Inducing cellular immune responses to hepatitis B virus...

Details Inducing cellular immune responses to hepatitis B virus... Inducing cellular immune responses to hepatitis B virus...

2003-09-04

2009-11-03

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S192100, C424S228100, C530S300000, C530S328000

Reexamination Certificate

active

07611713

ABSTRACT:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

REFERENCES:
patent: 4235877 (1980-11-01), Fullerton
patent: 4428941 (1984-01-01), Galibert et al.
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4837028 (1989-06-01), Allen
patent: 4882145 (1989-11-01), Thornton et al.
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5039522 (1991-08-01), Neurath
patent: 5128319 (1992-07-01), Arlinghaus
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5196194 (1993-03-01), Rutter et al.
patent: 5200320 (1993-04-01), Sette et al.
patent: 5360714 (1994-11-01), Seeger
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5788969 (1998-08-01), Chisari
patent: 5821048 (1998-10-01), Howley et al.
patent: 5840303 (1998-11-01), Chisari et al.
patent: 5932224 (1999-08-01), Chisari
patent: 6034214 (2000-03-01), Boon et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6235288 (2001-05-01), Chisari
patent: 6322789 (2001-11-01), Vitiello et al.
patent: 6365160 (2002-04-01), Webb et al.
patent: 6413935 (2002-07-01), Sette et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: 6534482 (2003-03-01), Fikes et al.
patent: 6602510 (2003-08-01), Fikes et al.
patent: 6607727 (2003-08-01), Chisari et al.
patent: 6689363 (2004-02-01), Sette et al.
patent: 2002/0098197 (2002-07-01), Sette et al.
patent: 2002/0160960 (2002-10-01), Sette et al.
patent: 2002/0168374 (2002-11-01), Kubo et al.
patent: 2002/0177694 (2002-11-01), Sette et al.
patent: 2003/0021809 (2003-01-01), Chisari et al.
patent: 2003/0143672 (2003-07-01), Tangri et al.
patent: 2003/0216342 (2003-11-01), Fikes et al.
patent: 2003/0216343 (2003-11-01), Fikes et al.
patent: 2004/0096445 (2004-05-01), Sidney et al.
patent: 2004/0157273 (2004-08-01), Sidney et al.
patent: 2005/0049197 (2005-03-01), Sette et al.
patent: 2005/0063983 (2005-03-01), Sette et al.
patent: 0 044 710 (1982-01-01), None
patent: 0 226 513 (1987-06-01), None
patent: 0 271 302 (1988-06-01), None
patent: 0 429 816 (1991-06-01), None
patent: 0 433 242 (1991-06-01), None
patent: 0 469 281 (1992-02-01), None
patent: 0 491 077 (1992-06-01), None
patent: 0 534 615 (1993-03-01), None
patent: 0 378 881 (1993-06-01), None
patent: 1 018 558 (2000-07-01), None
patent: WO 81/00577 (1981-03-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 92/12996 (1992-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/03753 (1993-03-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/11738 (1994-05-01), None
patent: WO 94/19011 (1994-09-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/03777 (1995-02-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 95/22317 (1995-08-01), None
patent: WO 96/03140 (1996-02-01), None
patent: WO 96/22067 (1996-07-01), None
patent: WO 97/34617 (1997-09-01), None
patent: WO 97/34621 (1997-09-01), None
patent: WO 97/41440 (1997-11-01), None
patent: WO 98/32456 (1998-07-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 99/58658 (1999-11-01), None
patent: WO 01/00225 (2001-01-01), None
patent: WO 02/19986 (2002-03-01), None
GenPept Accession AP 671816, core protein, NCBI printout, May 4, 1994.
Hosono et al., Virology, vol. 212 No. 1, pp. 151-162 (Sep. 1995).
Menne et al., Journal of Virology, vol. 75 No. 1, pp. 65-74 (Jan 1997).
Kast et al., Journal of Immunology, vol. 152 No. 8, pp. 3904-3912 (Apr. 1994).
Pinilla et al., Molecular Immunology, vol. 30 No. 6, pp. 577-585 (Apr. 1993).
Riffkin et al., Gene, vol. 167 No. 1-2, pp. 279-283 (Dec. 1995).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Sarobe et al., Journal of Clincial Investigation, vol. 10 No. 6, pp. 1239-1248 (Sep. 1998).
Bertoletti et al., Journal of Experimental Medicine, vol. 180 No. 3, pp. 933-943 (Sep. 1994).
Hasegawa et al., “Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis,” Journal of Virology, vol. 68 No. 3, pp. 1651-1659 (Mar. 1994).
GenPept AAA18580, “core antigen [Hepatitis B virus]”, first available Apr. 1994.
Alberti, A., et al., “Antibody Response to Pre-S2 and Hepatitis B Virus Induced Liver Damage,”Lancet 1:1421-1424, Lancet Publishing Group (1988).
Barnaba, V., et al., “Recognition of Hepatitis B Virus Envelope Proteins by Liver-Infiltrating T Lymphocytes in Chronic HBV Infection,”J. Immunol.143:2650-2655, American Association of Immunologists (1989).
Bertoletti, A., et al., “Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction with HLA and T-Cell Receptor,”Hepatology26:1027-1034, Williams & Wilkins (1997).
Cerny, A., et al, “Induction in vitro of a primary human antiviral cytotoxic T cell response,”Eur. J. Immunol. 25:627-630, VCH Verlagsgesellschaft (1995).
Jolivet, M., et al., “Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity,”Vaccine8:35-40, Butterworth & Co. (1990).
Kuhröber, A., et al., “DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes,”Int. Immunol. 9:1203-1212, Oxford University Press (1997).
Livingston, B.D., et al., “Immunization with the HBV Core 18-27 Epitope Elicits CTL Responses In Humans Expressing Different HLA-A2 Supertype Molecules,”Hum. Immunol. 60:1013-1017, Elsevier Science (Nov. 1999).
Livingston, B.D., et al., “The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination are Comparable to Those Elicited by Acute Viral Infection,”J. Immunol. 159:1383-1392, American Association of Immunologists (1997).
Milich, D.R., “T- and B-cell recognition of hepatitis B viral antigens,”Immunol. Today9:380-386, Elsevier Science (1988).
Milich, D.R., and Chisari, F.V., “Immunogenetics and Cellular Correlates of the Immune Response to Hepatitis B Surface Antigen Determinants,” inAdvances in Hepatitis Research, Chisari, F.V., ed., Masson Publishing Co., New York, NY, pp. 91-109 (1984).
Missale, G., et al., “HLA-A31- and HLA-Aw68-restricted Cytotoxic T Cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis,”J. Exp. Med. 177:751-762, Rockefeller University Press (1993).
Moriyama, T., et al., “Immunobiology and Pathogenesis of Hepatocellular Injury in Hepatitis B Virus Transgenic Mice,”Science248:361-364, American Association for the Advancement of Science (1990).
Neurath, A.R., et al., “Specificity of Antibodies Elicited by a Synthetic Peptide Having a Sequence in Common with a Fragment of a Virus Protein—The Hepatitis B Surface Antigen,”Dev. Biol. Stand. 54:103-112, S. Karger (1983).
Oseroff, C., et al., “Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses,”Vaccine16:823-833, Elsevier Science (Apr. 1998).
Schulz, M., et al., “Peptide-induced antiviral protection by cytotoxic T cells,”Proc. Natl. Acad. Sci. USA88:991-993, National Academy of Sciences (1991).
Sidney, J., et al., “DRB1*0301 Molecules Recognize a Structural Motif Distinct from the One Recognized by Most DR β1Alleles,”J. Immunol. 149:2634-2640, American Association of Immunologists (1992).
Sobao, Y., et al.,

Affiliated with

Also associated with

Rating

Inducing cellular immune responses to hepatitis B virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inducing cellular immune responses to hepatitis B virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducing cellular immune responses to hepatitis B virus... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4120839